In Depth 3 Mar 2023
Let’s Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to Treat
While we mostly think of disease as being caused by bacteria or viruses, an illness can often occur when the…
Dermatology
- Latest Posts
News and Trends 30 Nov 2022
TrialSpark acquires immunodermatology portfolio and creates Libertas Bio
TrialSpark has announced the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology…
News and Trends 3 Oct 2022
Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo
Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on…
News and Trends 29 Sep 2022
Treatment for adults with chronic skin condition approved by FDA
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.…
ADVERTISEMENT
News and Trends 19 Sep 2022
Kamari Pharma raises $8M in investment for development of drugs for skin diseases
An $8 million investment has been raised by Kamari Pharma following investment from the Guangzhou-Israel Biotechnology Fund (GIBF) that creates…
News and Trends 16 Sep 2022
Regeneron and Sanofi announce published trial results in children with dermatitis
Positive results from a phase 3 trial in children aged 6 months to five years old with uncontrolled moderate-to-severe dermatitis…
News and Trends 8 Sep 2022
Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M
Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused…
News and Trends 21 Jul 2022
Almirall launches new call to find innovative therapies for skin diseases
A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A.…
News and Trends 19 Feb 2018
Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown?
Two clinical studies have demonstrated the capacity of Novartis' monoclonal antibody to treat both plaque and scalp psoriasis and improve…
News and Trends 19 Feb 2018
This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline
UCB has presented positive Phase IIb results for its psoriasis drug, bimekizumab, and outlined the Phase III testing of Cimzia…
ADVERTISEMENT
News and Trends 23 Nov 2017
Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe
Following its FDA approval in July, MorphoSys’ anti-IL23 antibody has been approved to treat moderate-to-severe psoriasis by the European Commission. German…
In Depth 17 Oct 2017
Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis
Though the psoriasis market is teeming with effective products, companies have developed ways to devise new, more effective modes of…
News and Trends 2 Oct 2017
Update: The EU Approval of Dupixent Might Bring its Pricing Polemic to Europe
Update (01/10/2017): The European Commission has tighter control over pricing that governments have over here Images via Tero Vesalainen, Roman…
News and Trends 18 Sep 2017
Update: After 25 years, MorphoSys Gets its First Antibody Approved
Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to…
News and Trends 20 Jul 2017
Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links
Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that…
Interview 4 May 2017
This Belgian Startup is building the Next Generation of Diagnostic Tests
DNAlytics changes the diagnosing game. The company builds in vitro diagnosis tests that save many years for patients! I met…
ADVERTISEMENT
News and Trends 30 Mar 2017
Merck Outsources the Development of its Nanobody for Psoriasis
Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase…
News and Trends 29 Mar 2017
Get Ready for One of the Biggest New Drug Approvals of the Year
After Praluent, Sanofi and Regeneron have now scored their next drug approval with dupilumab, an antibody for the treatment of atopic dermatitis. With…
Best in Biotech 22 Dec 2016
The 10 Biggest Clinical Success Stories of 2016 in European Biotech
What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here's a list of…
News and Trends 2 Nov 2016
Antibody Therapies are here to Revolutionize Dermatology
Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field…